NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW – Get Free Report) saw a large increase in short interest in October. As of October 30th, there was short interest totaling 5,262 shares, an increase of 473.2% from the October 15th total of 918 shares. Based on an average daily trading volume, of 2,157 shares, the days-to-cover ratio is currently 2.4 days.
NeuroSense Therapeutics Stock Down 6.1%
Shares of NASDAQ NRSNW traded down $0.00 during midday trading on Friday, reaching $0.01. 23,085 shares of the company traded hands, compared to its average volume of 3,754. NeuroSense Therapeutics has a 12 month low of $0.00 and a 12 month high of $0.47. The stock’s 50-day simple moving average is $0.03 and its 200-day simple moving average is $0.12.
NeuroSense Therapeutics Company Profile
NeuroSense Therapeutics Ltd. is an Israel-based clinical-stage biotechnology company developing treatments for neurodegenerative diseases. Its research focuses on biological processes associated with nerve-cell damage and disease progression. The company’s lead investigational product, PrimeC, is an oral formulation combining ciprofloxacin and celecoxib. NeuroSense is developing PrimeC primarily for amyotrophic lateral sclerosis (ALS); it is investigational and has not been approved as a treatment.
Featured Articles
- Five stocks we like better than NeuroSense Therapeutics
- Costco’s Record $30 Dividend Shows Just How Strong Its Cash Machine Is
- Heavy Lifting: Can USA Rare Earth Turn Its First Sales Into Big Profits?
- These 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?
- Golden Dome’s $185 Billion Question: Who Actually Gets Paid?
Receive News & Ratings for NeuroSense Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroSense Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
